Treatment of Malignant Metastatic Midgut Carcinoid Tumours with Recombinant Human o2b Interferon with or without Prior Hepatic Artery Embolization

References

• Biörck G, Axén O, Thorson Å. Unusual cyanosis in a boy with congenital pulmonary stenosis and tricuspid insufficiency. Fatal outcome after angiocardiography. Am Heart J 1952; 44: 143–148
   PubMed Web of Science ®Google Scholar
• Davis Z, Moertel C G, McIlrath D C. The malignant carcinoid syndrome. Surg Gynecol Obstet 1973; 137: 637–644
   PubMedGoogle Scholar
• Davies A J. Carcinoid tumours (argentaffinomata). Ann R Coll Surg Engl 1959; 25: 277–297
   PubMedGoogle Scholar
• Moertel C G, Sauer W G, Dockerty M B, Bag-Genstoss A H. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14: 901–912
   PubMed Web of Science ®Google Scholar
• Moertel C G. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1983; 1: 727–740
   PubMed Web of Science ®Google Scholar
• Kowlessar O D, Law D H, Sleisenger M H. Malabsorption syndrome associated with metastatic carcinoid tumor. Am J Med 1959; 27: 673–677
   PubMed Web of Science ®Google Scholar
• Murray-Lyon I M, Rake M O, Marshall A K, Williams R. Malignant carcinoid tumour with gangrene of the small intestine. Br Med J 1973; 4: 770–771
   PubMedGoogle Scholar
• Sworn M J, Reasbeck P, Buchanan R. Intestinal ischaemia associated with ileal carcinoid tumours. Br J Surg 1978; 65: 313–315
   PubMedGoogle Scholar
• Kvols L K. Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy. A selective review of Am J Med 1986; 81(suppl 6B)49–55
   PubMed Web of Science ®Google Scholar
• Kvols L K, Moertel C G, O'Connell M J, Schutt A J, Rubin J, Hahn R G. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315: 663–666
   PubMed Web of Science ®Google Scholar
• Bengmark S, Nobin A, Jeppsson B, Tranberg K-G. Transient repeated dearterialization combined with intra-arterial infusion of oncolytic drugs in the treatment of liver tumors. Recent Results Cancer Res 1983; 86: 68–74
   PubMedGoogle Scholar
• Maton P N, Camilleri M, Griffin G, Allison D J, Hodgson H JF, Chadwick V S. Role of hepatic arterial embolisation in the carcinoid syndrome. Br Med J 1983; 287: 932–935
   PubMed Web of Science ®Google Scholar
• Mårtensson H, Nobin A, Bengmark S, Lunderquist A, Owman T, Sandbn G. Embolization of the liver in the management of metastatic carcinoid tumors. J Surg Oncol 1984; 27: 152–158
   PubMed Web of Science ®Google Scholar
• Mitty H A, Warner R RP, Newman L H, Train J S, Parnes I H. Control of carcinoid syndrome with hepatic artery embolization. Radiology 1985; 155: 623–626
   PubMed Web of Science ®Google Scholar
• Öberg K, Funa K, Aim G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with midgut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983; 309: 129–133
   PubMed Web of Science ®Google Scholar
• Hanssen L E, Schrumpf E, Kolbenstvedt A N, Tausjø J, Dolva L Ø. Recombinant human alpha2-interferon in the treatment of malignant metastatic midgut carcinoid tumours. J Interferon Res 1987; 7: 735
   Google Scholar
• Udenfriend S, Titus E, Weissbach H. The identification of 5-hydroxy-3-indoleacetic acid in normal urine and a method for its assay. J Biol Chem 1955; 216: 499–505
   PubMed Web of Science ®Google Scholar
• Goldenberg H. Specific photometric determination of 5-hydroxyindoleacetic acid in urine. Clin Chem 1973; 19: 38–44
   PubMed Web of Science ®Google Scholar
• Lunderquist A, Ericsson M, Nobin A, Sandiin G. Gelfoam powder embolization of the hepatic artery in liver metastases of carcinoid tumors. Radiologe 1982; 22: 65–70
   PubMed Web of Science ®Google Scholar
• Kvols L K, Martin J K, Marsh H M, Moertel C G. Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med 1985; 313: 1229–1230
   PubMed Web of Science ®Google Scholar
• Spiegel R J. Intron A (interferon alpha-2b): clinical overview and future directions. Semin Oncol 1986; 13(suppl 2)89–101
   PubMedGoogle Scholar
• Gutterman J U, Fine S, Quesada J, et al. Recombinant leukocyte a interferon: pharmakokinetics, single-dose tolerance, and biological effects in cancer patients. Ann Intern Med 1982; 96: 549–556
   PubMed Web of Science ®Google Scholar
• Protzman W P, Jacobs S L, Minnicozzi M, Oden E M, Kelsey D K. A radioimmunologic technique to screen for antibodies to α-2 interferon. J Immunol Methods 1984; 75: 317–323
   PubMedGoogle Scholar
• Yeh T-J, McBride P T, Overall J C, Green J A. Automated, quantitative cytopathic effect reduction assay for interferon. J Clin Microbiol 1982; 16: 413–415
   PubMedGoogle Scholar
• Berge T, Linell F. Carcinoid tumours. Frequency in a defined population during a 12-year-period. Acta Pathol Microbiol Scand [A] 1976; 84: 322–330
   PubMedGoogle Scholar
• Goodwin J D, II. Carcinoid tumors. An analysis of 2837 cases. Cancer 1975; 36: 560–569
   PubMed Web of Science ®Google Scholar
• Zeitels J, Naunheim K, Kaplan E L, Straus F, II. Carcinoid tumors. A 37-year experience. Arch Surg 1982; 117: 732–737
   PubMedGoogle Scholar
• Norheim I, Öberg K, Theodorsson-Norheim E, et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987; 206: 115–125
   Google Scholar
• Feldman J M. Urinary serotonin in the diagnosis of carcinoid tumors. Clin Chem 1986; 32: 840–844
   PubMed Web of Science ®Google Scholar
• Theodorsson-Norheim E, Norheim I, Öberg K, et al. Neuropeptide K: a major tachykinin in plasma and tumor tissues from carcinoid patients. Biochem Biophys Res Commun 1985; 131: 77–83
   PubMed Web of Science ®Google Scholar
• Norheim I, Theodorsson-Norheim E, Brodin E, Öberg K. Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush. J Clin Endocrinol Metab 1986; 63: 605–612
   PubMed Web of Science ®Google Scholar
• Jaffe B M. Prostaglandins and serotonin: non-peptide diarrheogenic hormones. World J Surg 1979; 3: 565–578
   PubMedGoogle Scholar
• Andersson T, Eriksson B, Hemmingsson A, Lindgren P G, Öberg K. Angiography, computed tomography, magnetic resonance imaging and ultrasonography in detection of liver metastases from endocrine gastrointestinal tumours. Acta Radiol 1987; 28: 535–539
   PubMed Web of Science ®Google Scholar
• Coupe M, Hemmingway A, Hodgson H JF, Allison D J. Effect of hepatic artery embolisation on survival in carcinoid syndrome. Gut 1987; 28: A1329
   Google Scholar
• Hersey P. The evolving role of alpha interferon in the treatment of malignancies. Aust NZ J Med 1986; 16: 425–437
   PubMedGoogle Scholar
• Herberman R B. Cancer therapy by biological response modifiers. Drug Res 1987; 37: 246–250
   Web of Science ®Google Scholar
• Spiegel R J, Spicehandler J R, Jacobs S L, Oden E M. Low incidence of serum neutralizing factors in patients receiving recombinant alpha-2b interferon (Intron A). Am J Med 1986; 80: 223–228
   PubMed Web of Science ®Google Scholar
• Quesada J R, Gutterman J U. Psoriasis and alpha-interferon. Lancet 1986; 1: 1466–1468
   PubMedGoogle Scholar
• Quesada J R, Talpaz M, Rios A, Kurzrock R, Gutterman J U. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 4: 234–243
   PubMed Web of Science ®Google Scholar
• Real F X, Krown S E, Nisce L Z, Oettgen H F. Unexpected toxicity from radiation therapy in two patients with Kaposi's sarcoma receiving interferon. J Biolog Response Modifiers 1985; 4: 141–146
   PubMedGoogle Scholar
• Torristi J, Berg C, Bonnem E, Dritschiio A. The combined use of interferon and radiotherapy in cancer management. Semin Oncol 1986; 13(suppl 2)78–83
   PubMedGoogle Scholar
• Keane T J, Rider W D, Harwood A R, et al. Whole abdominal radiation in the management of metastatic gastro-intestinal carcinoid tumor. Int J Radiat Oncol Biol Phys 1981; 7: 1519–1521
   PubMed Web of Science ®Google Scholar
• Samlowski W E, Eyre H J, Sanse W T. Evaluation of the response of unresectable carcinoid tumors to radiotherapy. Int J Radiat Oncol Biol Phys 1986; 12: 301–305
   PubMed Web of Science ®Google Scholar
• Souquet J-C, Sassolas G, Forichon J, Champetier P, Partensky C, Chayvialle J-A. Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome. Cancer 1987; 59: 1654–1660
   PubMedGoogle Scholar
• Ahlman H, Tisell L-E. The use of a long-acting somatostatin analogue in the treatment of advanced endocrine malignancies with gastrointestinal symptoms. Scand J Gastroenterol 1987; 22: 938–942
   PubMed Web of Science ®Google Scholar